Evidence map›Paper›PMID 38468326›Full record

ArticleBreast cancer research : BCR2024

Cell morphology best predicts tumorigenicity and metastasis in vivo across multiple TNBC cell lines of different metastatic potential.

Sydney J Conner, Justinne R Guarin, Thanh T Le, Jackson P Fatherree, Charlotte Kelley, Samantha L Payne, Savannah R Parker, Hanan Bloomer, Crystal Zhang, Kenneth Salhany and 6 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Altered Cell SurfaceJournal of proteome research · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Design, synthesis, characterization,Future medicinal chemistry · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Sydney J ConnerDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Justinne R GuarinDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Thanh T LeDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Jackson P FatherreeDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Charlotte KelleyDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Samantha L PayneDepartment of Biomedical Sciences, University of Guelph, 50 Stone Rd E, Guelph, ON, Canada.
Savannah R ParkerDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Hanan BloomerDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Crystal ZhangDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Kenneth SalhanyDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Rachel A McGinnDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Emily HenrichDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Anna YuiDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Deepti SrinivasanDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Hannah BorgesDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA.
Madeleine J OudinDepartment of Biomedical Engineering, Tufts University, 200 College Ave, Medford, MA, 02155, USA. madeleine.oudin@tufts.edu.
Tufts University · USUniversity of Guelph · CA

Funding

Defining and Exploiting the Neuronal Identity of CancersDP2CA271387 · NCI · TUFTS UNIVERSITY MEDFORD · PI OUDIN, MADELEINE JULIE · 2021 to 2024
$2.3M
Investigating mechanisms of chemoresistance in triple-negative breast cancerR01CA255742 · NCI · TUFTS UNIVERSITY MEDFORD · PI Madeleine Julie Oudin · 2022 to 2026
$1.8M
Research Training Program in Nutrition, Obesity and Metabolic DisordersT32DK124170 · NIDDK · TUFTS UNIVERSITY BOSTON · PI GREENBERG, ANDREW S · 2020 to 2024
$870k
Investigating the role of the extracellular matrix in metastasis and chemo-resistanceR00CA207866 · NCI · TUFTS UNIVERSITY MEDFORD · PI OUDIN, MADELEINE JULIE · 2018 to 2020
$696k
NCI NIH HHS DP2 CA271387NCI NIH HHS DP2CA271387NCI NIH HHS R00 CA207866NCI NIH HHS R00-CA207866NCI NIH HHS R01 CA255742NCI NIH HHS R01CA255742NIDDK NIH HHS 1T32DK124170-01NIDDK NIH HHS T32 DK124170
6 · The paper itself

Abstract

backgroundMetastasis is the leading cause of death in breast cancer patients. For metastasis to occur, tumor cells must invade locally, intravasate, and colonize distant tissues and organs, all steps that require tumor cell migration. The majority of studies on invasion and metastasis rely on human breast cancer cell lines. While it is known that these cells have different properties and abilities for growth and metastasis, the in vitro morphological, proliferative, migratory, and invasive behavior of these cell lines and their correlation to in vivo behavior is poorly understood. Thus, we sought to classify each cell line as poorly or highly metastatic by characterizing tumor growth and metastasis in a murine model of six commonly used human triple-negative breast cancer xenografts, as well as determine which in vitro assays commonly used to study cell motility best predict in vivo metastasis.

methodsWe evaluated the liver and lung metastasis of human TNBC cell lines MDA-MB-231, MDA-MB-468, BT549, Hs578T, BT20, and SUM159 in immunocompromised mice. We characterized each cell line's cell morphology, proliferation, and motility in 2D and 3D to determine the variation in these parameters between cell lines.

resultsWe identified MDA-MB-231, MDA-MB-468, and BT549 cells as highly tumorigenic and metastatic, Hs578T as poorly tumorigenic and metastatic, BT20 as intermediate tumorigenic with poor metastasis to the lungs but highly metastatic to the livers, and SUM159 as intermediate tumorigenic but poorly metastatic to the lungs and livers. We showed that metrics that characterize cell morphology are the most predictive of tumor growth and metastatic potential to the lungs and liver. Further, we found that no single in vitro motility assay in 2D or 3D significantly correlated with metastasis in vivo.

conclusionsOur results provide an important resource for the TNBC research community, identifying the metastatic potential of 6 commonly used cell lines. Our findings also support the use of cell morphological analysis to investigate the metastatic potential and emphasize the need for multiple in vitro motility metrics using multiple cell lines to represent the heterogeneity of metastasis in vivo.

Indexed as

Triple Negative Breast NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationHeterograftsHumansMiceTransplantation, HeterologousAdhesionCell linesInvasionMetastasisMigrationTriple-negative breast cancer

Identifiers

PMID38468326
PMCPMC10929179
OpenAlexW4392643191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.